Optimi Health Stock Price, News & Analysis

Optimi Health Corp. announced three new distribution agreements for its Optimi Life nutraceutical mushroom products with Well.ca, Vitasave, and Healthy Planet. These deals enhance the company's B2B distribution network and are expected to facilitate its expansion into international markets. The agreements come shortly after the successful February launch of Optimi Life, which aims to meet the growing consumer demand for high-quality mushroom products. CEO Bill Ciprick highlighted the anticipated growth in the functional mushroom market, projected to expand by 9.5% annually over the next six years.

Optimi Health Corp. has received permission from Health Canada to manufacture and distribute MDMA and additional psychedelics, enhancing its position as a global leader in this sector. The company plans to begin production of MDMA in October 2022 at its EU-GMP approved facility. This amendment supports Optimi's commercialization strategy, with CEO Bill Ciprick emphasizing operational transparency and regulatory compliance. Optimi also aims to address growing market needs amidst evolving regulatory landscapes in Canada and the U.S., with increasing interest from clinical trial researchers and drug developers.

Optimi Health Corp. (OTCQX: OPTHF) has launched Blue Serenity, Canada's first natural psilocybin product, in collaboration with psilocybin advocate Thomas Hartle. This product contains 25 mg of psilocybin derived from Panaeolus cyanescens mushrooms, aiming to assist patients under Canada's Special Access Program. Proceeds will benefit psilocybin therapy access for underserved adults through Hartle's new charity. The company will also donate $5,000 to this initiative. The launch reflects Optimi's commitment to compassionate care and expanding access to psychedelic therapies.

Optimi Health Corp. has secured a supply agreement with Bloom Psychedelic Therapy And Research Centre to provide natural psilocybin for clinical trials aimed at enhancing mental health. This partnership is positioned to establish Canada as a leader in psychedelics, leveraging Optimi's GMP-grade psilocybin and Bloom's therapeutic expertise. The initial phase I study will explore the optimal low doses of psilocybin for improving overall well-being without hallucinogenic effects. This follows Optimi's development of a state-of-the-art 20,000 sq ft facility for psilocybin production in British Columbia.

Optimi Health Corp (CSE: OPTI, OTCQX: OPTHF) has entered a supply agreement with Calgary-based SABI Mind for the provision of GMP psilocybin and MDMA. This agreement enables SABI's clinical staff to utilize these substances in psychedelic-assisted therapies pending licensing approval from Health Canada. The collaboration marks a significant milestone in Canada’s psychedelics sector, aiming to address mental health conditions like PTSD and depression. Optimi is also pursuing an amendment to its Controlled Substance Dealer’s Licence to enhance its capabilities in synthetic MDMA production.

Optimi Health Corp has submitted a request to Health Canada for an amendment to its Controlled Substances Dealer’s Licence to synthesize and distribute pharmaceutical-grade MDMA at its facility in Princeton, British Columbia. This move is part of the company’s strategy to commercialize synthetic psychedelics, capitalizing on growing demand in research, especially from Phase III MDMA studies led by MAPS. Optimi aims to expand its offerings and improve revenue generation through standardized drug testing and clinical trials.

Optimi Health Corp. (OTCQX: OPTHF) has entered a strategic supply agreement with ATMA Journey Centers to provide psilocybin products for therapist training and therapy initiatives. This partnership aims to improve regulatory outcomes and enhance mental health services. Optimi will supply high-quality psilocybin to support research and training for therapists, contributing to the evolving landscape of psilocybin-assisted therapy. The collaboration is expected to refine commercial distribution and clinical applications of psilocybin, preparing for increasing demand as research advances.

Optimi Health Corp. (OTCQX: OPTHF) has announced a one-year supply agreement with Filament Health for psilocybin mushrooms cultivated at its EU-GMP facility in Princeton, British Columbia. The deal allows Filament to order whole, dried mushroom fruiting bodies for drug development purposes. Both companies aim to enhance the safety and supply of natural psilocybin, which is actively being studied in clinical trials worldwide. This collaboration aligns with Optimi's goal to be a trusted provider of safe, natural psilocybin and functional mushrooms.

Optimi Health Corp. (OTCQX: OPTHF) has announced a supply agreement with Halucenex Life Sciences Inc. for the provision of its first batch of psilocybe cubensis mushrooms, harvested from its facility in Princeton, British Columbia. This agreement is a significant step following Optimi's initial cultivation cycle and aims to meet the growing demand for GMP-grade psilocybin. The company has received a dealer's license allowing possession of up to 5000 kg of dried psilocybin mushrooms. This partnership supports Halucenex's research into psychedelic-assisted therapy for PTSD and anxiety.